Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles

References

• Asaki T, Kuwano K, Morrison K, Gatfield J, Hamamoto T, Clozel M. 2015. Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem. 58(18):7128–7137.
   PubMed Web of Science ®Google Scholar
• A Xe Lsen LN, Poggesi I, Rasschaert F, Ruixo J, Bruderer S. 2021. Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. Br J Clin Pharmacol. 87(1):119–128.
   PubMed Web of Science ®Google Scholar
• Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. 2004. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 43(12 Suppl S):56S–61s.
   PubMed Web of Science ®Google Scholar
• Bhadru B, Rao VV, Vidhyadhara S. 2019. Development and validation of bioanalytical method for the quantitative estimation of selexipag in biological matrices using LC-MS/MS. Pharm Sci Res. 11:2722–2727.
   Google Scholar
• Bruderer S, Hurst N, Remenova T, Dingemanse J. 2017. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 16(6):743–751.
   PubMed Web of Science ®Google Scholar
• Bruderer S, Petersen-Sylla M, Boehler M, Remeňová T, Halabi A, Dingemanse J. 2017. Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects. Br J Clin Pharmacol. 83(12):2778–2788.
   PubMed Web of Science ®Google Scholar
• Cao L, Kwara A, Greenblatt DJ. 2017. Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 69(12):1762–1772.
   PubMed Web of Science ®Google Scholar
• Chandrasekaran SK, Benson H, Urquhart J. 1978. Methods to achieve controlled drug delivery: the biomedical engineering approach. In: Robinson JR, ed. Sustained and controlled release drug delivery systems. New York: Marcel Dekker; p. 557–593.
   Google Scholar
• Dabeek WM, Marra MV. 2019. Dietary quercetin and kaempferol: bioavailability and potential cardiovascular-related bioactivity in humans. Nutrients. 11(10):2288–2306.
   PubMed Web of Science ®Google Scholar
• Elbarbry F, Ung A, Rao D, Abdelkawy K. 2019. Effect of dietary doses of quercetin on hepatic drug metabolizing enzymes in spontaneously hypertensive rats. Eur J Drug Metab Pharmacokinet. 44(6):761–770.
   PubMed Web of Science ®Google Scholar
• Fischer C, Speth V, Fleig-Eberenz S, Neuhaus G. 1997. Induction of zygotic polyembryos in wheat: influence of auxin polar transport. Plant Cell. 9(10):1767–1780.
   PubMed Web of Science ®Google Scholar
• Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O. 2017. Selexipag active metabolite ACT-333679 displays strong anticontractile and antiremodeling effects but low β-arrestin recruitment and desensitization potential. J Pharmacol Exp Ther. 362(1):186–199.
   PubMed Web of Science ®Google Scholar
• Genecand L, Wacker J, Beghetti M, Lador F. 2021. Selexipag for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med. 15(5):583–595.
   PubMed Web of Science ®Google Scholar
• Gnerre C, Segrestaa J, Seeland S, Äänismaa P, Pfeifer T, Delahaye S, de Kanter R, Ichikawa T, Yamada T, Treiber A. 2018. The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag. Xenobiotica. 48(7):704–719.
   PubMed Web of Science ®Google Scholar
• Health UDo, Human services F, Drug Administration CfDE, Research CfVm. 2001. Guidance for industry, bioanalytical method validation. Fed Regist. 66:206–207.
   Google Scholar
• Highland KB, Hull M, Pruett J, Elliott C, Tsang Y, Drake W. 2019. Baseline history of patients using selexipag for pulmonary arterial hypertension. Ther Adv Respir Dis. 13:1753466619843774.
   Web of Science ®Google Scholar
• Ichikawa T, Yamada T, Treiber A, Gnerre C, Segrestaa J, Seeland S, Nonaka K. 2019. Cross-species comparison of the metabolism and excretion of selexipag. Xenobiotica. 49(3):284–301.
   PubMed Web of Science ®Google Scholar
• Ilyin NV, Ivanov KI, Martynyuk TV. 2019. New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag. Cardiovasc Ther Prev. 18(6):80–87.
   Google Scholar
• Imai S, Ichikawa T, Sugiyama C, Nonaka K, Yamada T. 2019. Contribution of human liver and intestinal carboxylesterases to the hydrolysis of selexipag in vitro. J Pharm Sci. 108(2):1027–1034.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Cruz HG, Krause A, Ulč I, Halabi A, Dingemanse J. 2016. Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. Br J Clin Pharmacol. 82(2):369–379.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Niglis S, Bruderer S, Segrestaa J, Äänismaa P, Halabi A, Dingemanse J. 2015a. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol. 80(4):670–677.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, Mukai H. 2015b. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 15(3):195–203.
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Kim HK, Ha JM, Park JY. 2005. Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. J Clin Pharmacol. 45(8):941–946.
   PubMed Web of Science ®Google Scholar
• Klose H, Chin K, Ewert R, Gall H, Parambil J, Poch D, Seyfarth H, Axelsen L, Schmitz SH, Stein C, et al. 2019. Safety, tolerability and pharmacokinetics study in patients with pulmonary arterial hypertension (PAH) temporarily switching from oral to IV selexipag. J Heart Lung Transplantation. 38(4):S490–S490.
   Web of Science ®Google Scholar
• Klose H, Chin KM, Ewert R, Gall H, Parambil J, Poch D, Seyfarth H-J, Axelsen LN, Hsu Schmitz S-F, Stein C, et al. 2021. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. Respir Res. 22(1):34–42.
   PubMed Web of Science ®Google Scholar
• Pang CY, Mak JW, Ismail R, Ong CE. 2012. In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8). Naunyn Schmiedebergs Arch Pharmacol. 385(5):495–502.
   PubMed Web of Science ®Google Scholar
• Projean D, Morin PE, Tu TM, Ducharme J. 2003. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica. 33(8):841–854.
   PubMed Web of Science ®Google Scholar
• Sardana M, Moll M, Farber HW. 2016. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 12(12):1513–1520.
   PubMed Web of Science ®Google Scholar
• Xie S, Shi L, Chen J, Xu RA, Ye X. 2020. Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method – ScienceDirect. J Pharm Biomed Anal. 190:113496–113501.
   PubMed Web of Science ®Google Scholar
• Yazıcı O, Güngör H. 2019. Selexipag: a new treatment agent for pulmonary arterial hypertension. Meandros. 20(1):1–6. DOI:10.4274/meandros.galenos.2017.20592.
   Web of Science ®Google Scholar